ClinicalTrials.gov, 2023) conducted a comparative study of the PI3K inhibitor alpelisib plus fulvestrant and placebo plus fulvestrant in men and postmenopausal women diagnosed with PIK3CA-mutated HR+/HER2-advanced breast cancer. Here, ERBB2 is linked to breast cancer.